Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OBIO
OBIO logo

OBIO News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

OBIO News

Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy

Apr 30 2026Newsfilter

AVIM Therapy Shows Significant Blood Pressure Reduction

Apr 23 2026Newsfilter

Orchestra BioMed and Medtronic Collaborate on AVIM Therapy Development for Hypertension

Dec 08 2025Globenewswire

Orchestra BioMed and Medtronic Collaborate on AVIM Therapy Development

Dec 08 2025Newsfilter

Orchestra BioMed Grants 151,250 Stock Options to 12 New Employees

Nov 26 2025Newsfilter

Orchestra BioMed to Attend Upcoming Conferences for Institutional Investors

Nov 11 2025Newsfilter

Orchestra BioMed Holdings Reports Increased Loss in Q3

Nov 10 2025NASDAQ.COM

Orchestra BioMed announces secondary offering of approximately 8 million shares

Nov 03 2025SeekingAlpha

OBIO Events

05/06 09:11
Orchestra BioMed Receives $15M Payment from Ligand
Orchestra BioMed (OBIO) announced the receipt of a $15M payment from Ligand (LGND) pursuant to the previously disclosed revenue participation right purchase and sale agreement. The payment completes a scheduled tranche under the agreement and reflects Ligand's continued strategic capital support of Orchestra BioMed's late-stage cardiovascular programs, AVIM Therapy and Virtue SAB, which are both being evaluated in ongoing randomized, controlled pivotal trials. The $15M investment follows an initial $20M investment received at closing of the initial tranche under the royalty purchase agreement on August 4, 2025 and completes Ligand's $35M royalty financing commitment under the royalty purchase agreement. As previously announced, Ligand also purchased an additional $5M of Orchestra BioMed common stock in an equity private placement in August 2025. This payment, together with a $20M investment from Medtronic announced separately, represents a total of $35M in fresh strategic capital received by Orchestra BioMed on May 1 under previously disclosed agreements.
04/30 10:00
Orchestra BioMed Receives Second Breakthrough Device Designation from FDA
Orchestra BioMed (OBIO) announced that the FDA has granted a second breakthrough device designation, or BDD, for AVIM therapy specific to patients with uncontrolled hypertension despite the use of anti-hypertensive medications, and an indication for a pacemaker. Together, the two BDDs for AVIM therapy cover indications that encompass both the broader population of patients with uncontrolled hypertension despite medication and increased cardiovascular risk as well as the specific pacemaker-indicated population with uncontrolled hypertension being evaluated in the BACKBEAT trial, which Orchestra BioMed is conducting in collaboration with Medtronic (MDT).
03/12 16:20
Major Averages Drop Over 1% Amid Iran War
The major averages closed with losses of over 1% each as market volatility continues amid the war in Iran and the supply disruptions that are occurring because of it. Oil prices surged roughly 10% as Iran's new Supreme Leader Mojtaba Khamenei said the Strait of Hormuz should remain closed, while U.S. Energy Secretary Chris Wright told CNBC that the U.S. Navy is not prepared to escort oil tankers through the strait at this time. Overnight, three more foreign vessels were struck in the Persian Gulf a day after three separate ships, including one in the Strait, had been hit.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Dick's Sporting Goodsreportedand raised its annual dividendDollar Generalreportedand provided its outlook for FY26Morgan Stanleyand Cliffwater have capped withdrawals from their multibillion-dollar private credit funds after investors sought to redeem vastly more than the vehicles allow,Teamsters haveabout the upcoming merger of Paramount Skydanceand Warner Bros. DiscoveryAnthropic is investing $100M into the2. WALL STREET CALLS:Wells FargoOccidentalto Overweight, calling the company's "peer-leading oil sensitivity" both "an opportunity and a risk"CitiDow Inc.and LyondellBasellto Buy on "asymmetric upside risk" from an extended Middle East conflictJefferiesNutriento Buy on higher fertilizer pricesBernsteinCVSand Cignato OutperformMercadoLibreto Neutral at JPMorgan3. AROUND THE WEB:Telusis investigating a security breach, BleepingComputer reportsThe U.K.'s Ofgem has granted Teslalicense to supply electricity in the U.K., FT saysDeutsche Bankplans to expand its private credit business despite rising investor concerns about credit quality, with its portfolio reaching EUR 25.9B at the end of 2025, up about 6% year over year, FT reportsAbivaxsays "we deny the rumors" to Bloomberg after a report claimed the company granted AstraZenecaan exclusive period to access confidential information and formalize a potential takeover offerJPMorganand UBScut prime brokerage ties with Infini Capital Management Ltd. months ago, Bloomberg reports4. MOVERS:Lightwave Logicrose afterwith Tower SemiconductorPetcoincreased afterand providing guidance for FY26ProFrac Holdingsand Bumbleadvanced afterTIC Solutionsfell afterand announcing the planned retirement of CEO Tal PizzeyNetskopeand GPGIpulled back after5. EARNINGS/GUIDANCE:Gambling.comand provided guidance for FY26, with CEO Charles Gillespie calling out "record fourth quarter revenue"Sunbelt Rentalsand narrowed its guidance for FY26Vera Bradley, with CEO Ian Bickley commenting on "meaningful progress in our transformation journey"Orchestra BioMed, with EPS beating consensusVivid Seatsand provided guidance for Q1 and FY26INDEXES:The Dow fell 739.42, or 1.56%, to 46,677.85, the Nasdaq lost 404.15, or 1.78%, to 22,311.98, and the S&P 500 declined 103.18, or 1.52%, to 6,672.62.
03/12 12:00
Markets Volatile Amid Iran War, Oil Prices Surge Over 10%
The major averages were broadly lower near noon as market volatility continues amid the war in Iran and the supply disruptions that are occurring because of it. Oil prices surged over 10% as Iran's new Supreme Leader Mojtaba Khamenei said the Strait of Hormuz should remain closed, while U.S. Energy Secretary Chris Wright told CNBC that the U.S. Navy is not prepared to escort oil tankers through the strait at this time. Overnight, three more foreign vessels were struck in the Persian Gulf a day after three separate ships, including one in the Strait, had been hit.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Dick's Sporting Goodsreportedand raised its annual dividendDollar Generalreportedand provided its outlook for FY26Morgan Stanleyand Cliffwater have capped withdrawals from their multibillion-dollar private credit funds after investors sought to redeem vastly more than the vehicles allow,The Trump administration is planning to issue 30-day waivers for the Jones Act to allow foreign tankers to help supply refiners on the East Coast with fuel from the Gulf Coast and elsewhere in the U.S.,Rivianintroduced its R2 line, with deliveries slated to begin2. WALL STREET CALLS:Wells FargoOccidentalto Overweight, calling the company's "peer-leading oil sensitivity" both "an opportunity and a risk"CitiDow Inc.and LyondellBasellto Buy on "asymmetric upside risk" from an extended Middle East conflictJefferiesNutriento Buy on higher fertilizer pricesBernsteinCVSand Cignato OutperformMercadoLibreto Neutral at JPMorgan3. AROUND THE WEB:Deutsche Bankplans to expand its private credit business despite rising investor concerns about credit quality, with its portfolio reaching EUR 25.9B at the end of 2025, up about 6% year over year, FT reportsEstee Lauderhas filed a lawsuit against Jo Malone, her fragrance brand "Jo Loves" and Zara's UK business for the use of Malone's name on certain products as the U.S. firm owns the brand, Reuters reportsAbivaxsays "we deny the rumors" to Bloomberg after a report claimed the company granted AstraZenecaan exclusive period to access confidential information and formalize a potential takeover offerAnthropic is seeking a U.S. appeals court stay after being deemed a supply-chain risk by the Pentagon, Reuters reportsJPMorganand UBScut prime brokerage ties with Infini Capital Management Ltd. months ago, Bloomberg reports4. MOVERS:Lightwave Logicgains afterwith Tower SemiconductorPetcoincreases afterand providing guidance for FY26ProFrac Holdingsand Bumblehigher afterTIC Solutionsfalls afterand announcing the planned retirement of CEO Tal PizzeyNetskopeand GPGIlower after5. EARNINGS/GUIDANCE:Gambling.comand provided guidance for FY26, with CEO Charles Gillespie calling out "record fourth quarter revenue"Sunbelt Rentalsand narrowed its guidance for FY26Vera Bradley, with CEO Ian Bickley commenting on "meaningful progress in our transformation journey"Orchestra BioMed (OBIO)with EPS beating consensusVivid Seatsand provided guidance for Q1 and FY26INDEXES:Near midday, the Dow was down 1.13%, or 536.43, to 46,880.84, the Nasdaq was down 1.36%, or 309.41, to 22,406.73, and the S&P 500 was down 1.03%, or 69.63, to 6,706.17.

OBIO Monitor News

No data

No data

OBIO Earnings Analysis

No Data

No Data

People Also Watch